This job has expired

Director, Division of Medical Oncology

Job Details

Director, Division of Medical Oncology

Stop by and visit us at the Annual ASCO Conference - we have a booth this year in the Career Fair section - Booth #CF4!  

The Ohio State University (OSU) College of Medicine and Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and the OSU Comprehensive Cancer Center (OSUCCC-James) seek an exceptional academic physician with proven leadership skills to serve as the next Director of the Division of Medical Oncology.


The Division of Medical Oncology falls under the Department of Internal Medicine led by Rama Mallampalli, MD and Chair. The Division is composed of 56 physicians on the tenure or clinical track, 15 PhD Research Faculty, 85 inpatient and outpatient advanced practice practitioners, and 25 administrative support staff.  In fiscal year 2021, the Division had over 165 publications and $21.5 million in total external research funding including $8.5 million in NIH funding.

The next Director will grow the Division by increasing its presence on the national/international stage through innovative laboratory and clinical research, strengthening the educational mission and bolstering the delivery of leading-edge clinical care on a local, regional, and national level.  The successful candidate will possess the knowledge and experience to effectively lead physicians and other health professionals, researchers, and educators while embracing the values of inclusiveness, diversity and excellence. This leader should also embody the importance of mentoring, promoting talented junior faculty, led by consensus, and be a servant leader.

Qualified candidates must possess an MD, DO (with or without PhD), and board certification in Medical Oncology and be licensed or eligible for licensure to practice medicine in the state of Ohio. Proven and substantial leadership experience in an academic medical center is required, as is the ability to be a collaborative thought-leader in a large, matrixed, multi-faceted medical center.

The OSUCCC-James strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care — a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program’s 356-bed adult patient-care component, The James is the 3rd largest cancer hospital in the nation, ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. Please see our website for more detailed information on the OSUCCC-James including advanced clinical trials, 275+ world-renowned cancer researchers, accreditations, accolades, revolutionary targeted treatments, methods and therapies and survivorship programming. 


All inquiries, nominations, and applications with cover letter and curriculum vitae should be directed in confidence to: Trevor Bethel, CPRP, Manager, Physician and Faculty Recruitment



  The Ohio State University is an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status or protected veteran status.



OSU has one of the nation’s NCI designated Comprehensive Cancer Centers (CCC) and currently has 46 faculty members in the DHO that provide care in The James Cancer Hospital, one of 10 free-standing cancer hospitals in the country. The Division of Hematology and Oncology (DHO) and CCC have initiated disease-specific programs utilizing combined modality management of cancer patients. The OSU CCC participates in CALGB, RTOG and NSABP cooperative groups, and has an active Experimental Therapeutics Program that includes a cancer-specific phase I unit in the James Cancer Hospital, a Phase I U01 grant, and a Phase II contract.

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert